VEGF antagonist formulations suitable for intravitreal administration

Patent metadata

Field	Value
Publication number	US-9914763-B2
Application number	US-201615095606-A
Country	US
Kind code	B2
Filing date	Apr 11, 2016
Priority date	Jun 16, 2006
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4.

First claim

We claim:

1. A prefilled glass syringe suitable for intravitreal administration containing a stable ophthalmic formulation, comprising:
a vascular endothelial growth factor (VEGF) antagonist,
an organic co-solvent,
a buffer, and
a stabilizing agent,
wherein the VEGF antagonist is a fusion protein produced in a Chinese Hamster Ovary (CHO) cell, the fusion protein comprising an immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

2. The prefilled glass syringe of claim 1 , wherein 90% or more of the weight of the fusion protein is not present as an aggregate.

3. The prefilled glass syringe of claim 2 , wherein the first VEGF receptor is human Flt1 and the second VEGF receptor is selected from the group consisting of human Flk1 and the human Flt4.

4. The prefilled syringe of claim 3 comprising (a) 1-100 mg/ml of the VEGF antagonist; (b) 0.01-5% of the organic co-solvent; (c) 5-40 mM of the buffer; and (d) 1.0-10% of the stabilizing agent.

5. The prefilled glass syringe of claim 3 , wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:4.

6. The prefilled glass syringe of claim 5 , wherein the VEGF antagonist is a dimer of the fusion protein.

7. The prefilled syringe of claim 1 , wherein the organic co-solvent is selected for the group consisting of poylsorbate 20, polysorbate 90, polyethylene gycol (PEG), pPGE3350, and propylene glycol.

8. The prefilled syringe of claim 1 , wherein the stabilizing agent is selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol.

9. The prefilled syringe of claim 1 , wherein the buffer comprises phosphate.

10. The prefilled syringe of claim 1 , wherein the organic co-solvent is poylsorbate 20, the buffer is phosphate, and the stabilizing agent is sucrose.

11. A prefilled glass syringe suitable for intravitreal administration containing a stable ophthalmic formulation, comprising:
1-100 mg/ml of a vascular endothelial growth factor (VEGF) antagonist,
an organic co-solvent,
5-40 mM of a phosphate buffer, and
1.0-10% of a stabilizing agent is selected from the group consisting of sucrose, sorbitol, glycerol, trehalose, and mannitol;
wherein the VEGF antagonist is a fusion protein comprising an immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

12. A prefilled glass syringe suitable for intravitreal administration containing a stable ophthalmic formulation, comprising:
a vascular endothelial growth factor (VEGF) antagonist,
polysorbate 20,
a phosphate buffer, and
a sucrose,
wherein the VEGF antagonist is a fusion protein produced in a Chinese Hamster Ovary (CHO) cell, the fusion protein comprising an immunoglobin-like (Ig) domain 2 of a first VEGF receptor and Ig domain 3 of a second VEGF receptor, and a multimerizing component.

Assignees

• Regeneron Pharma

Inventors

• Furfine Eric
• Dix Daniel
• Graham Kenneth
• Frye Kelly

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K38/1793

  for cytokines; for lymphokines; for interferons · CPC title

• A61K9/19 Primary

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title